Plasma Transfusion and Use of Albumin

Rossi's Principles of Transfusion Medicine: Fourth Edition

Volumn , Issue , 2009, Pages 287-297

  Stanworth, Simon J ^a   Tinmouth, Alan T ^b,c,d  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991457539     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303513.ch20     Document Type: Chapter

References (81)

1. BCSH guidelines for the use of fresh frozen plasma (updated). Br J Haematol 2004;126:11-28.
2. Cardigan R, Lawrie AS, Mackie IJ, Williamson LM. The quality of fresh frozen plasma produced from whole blood stored at 4°C overnight. Transfusion 2005;45:1342-8.
3. Garwood M, Cardigan RA, Drummond O, et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh frozen plasma. Transfusion 2003;43:1238-47.
4. Wallis JP, Dzik S. Is fresh frozen plasma overtransfused in the United States? Transfusion 2004;44:1674-5.
5. Goodnough LT, Johnston MF, Shah T, Chernosky A. A two-institution study of transfusion practice in 78 consecutive adult elective open-heart procedures. Am J Clin Pathol 1989;91:468-72.
6. Tinmouth AT, Hutton B, Fergusson DA, Hebert PC. FFP and platelet transfusions are associated with increased mortality in cardiac surgery, critical care and hip fracture patients (abstract). Transfusion 2005;45(Suppl 3):35a.
7. Dzik W, Rao A. Why do physicians request fresh frozen plasma? Transfusion 2004;44:1393-4.
8. Palo R, Capraro L, Hovilehto S, et al. Population-based audit of fresh frozen plasma transfusion practices. Transfusion 2006;46:1921-5.
9. Metz J, McGrath KM, Copperchini ML, et al. Appropriateness of transfusions of red cells, platelets and fresh frozen plasma. An audit in a tertiary care teaching hospital. Med J Aust 1995;162:572-3.
10. Tobin SN, Campbell DA, Boyce NW. Durability of response to a targeted intervention to modify clinician transfusion practices in a major teaching hospital. Med J Aust 2001;174:445-8.
11. Shanberge JN, Quattrociocchi-Longe T. Analysis of fresh frozen plasma administration with suggestions for ways to reduce usage. Transfus Med 1992;2:189-94.
12. Hui CH, Williams I, Davis K. Clinical audit of the use of fresh-frozen plasma and platelets in a tertiary teaching hospital and the impact of a new transfusion request form. Intern Med J 2005;35:283-8.
13. Tuckfield A, Haeusler MN, Grigg AP, Metz J. Reduction of inappropriate use of blood products by prospective monitoring of transfusion request forms. Med J Aust 1997;167:473-6.
14. MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. J Trauma 2006;60:S46-S50.
15. Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 2007;131:1308-14.
16. Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev 2004;18:184-88.
17. Andrzejewski C, Popovsky MA. Transfusion-associated adverse pulmonary sequelae: Widening our Perspective. Transfusion 2005;45:1048-50.
18. Serious hazards of transfusion. Annual report 2005. Manchester, UK: SHOT Office, 2005. [Available at http://www.shotuk.org.]
19. Clarifications to recommendations to reduce the risk of TRALI. Association bulletin #07-03 (November 28, 2007). Bethesda, MD: AABB, 2007.
20. Practice parameter for the use of fresh-frozen plasma, cryopre- cipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA 1994;271:777-81.
21. Canadian Medical Association Expert Working Group. Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J 1997;156(11 suppl):S1-S24.
22. Roseff SD, Luban NLC, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 2002;42:1398-413.
23. Contreras M, Ala FA, Greaves M, et al. Guidelines for the use of fresh frozen plasma. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force. Transfus Med 1992;2:57-63.
24. NIH consensus conference. Fresh-frozen plasma. Indications and risks. JAMA 1985;253:551-3.
25. Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732-47.
26. De Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: A comparative review. Crit Care Med 2001;29:1261-7.
27. Stanworth SJ, Brunskill S, Hyde CJ, et al. What is the evidence base for the clinical use of FFP: A systematic review of randomised controlled trials. Br J Haematol 2004;126:139-52.
28. Northern Neonatal Nursing Initiative (NNNI) Trial Group. A randomized trial comparing the effect of prophylactic intravenous fresh frozen plasma, gelatin or glucose in preterm babies: Outcome at 2 years. Lancet 1996;348:229-32.
29. Leese T, Holliday M, Watkins M, et al. A multicentre controlled clinical trial of high-volume fresh frozen plasma therapy in prognostically severe acute pancreatitis. Ann R Coll Surg Engl 1991;73:207-14.
30. Casbard AC, Williamson LM, Murphy MF, et al. The role of prophylactic fresh frozen plasma in reducing blood loss and correcting coagulopathy in cardiac surgery: A systematic review. Anaesthesia 2004;59:550-8.
31. Bevan DH. Cardiac bypass haemostasis: Putting blood through the mill. Br J Haematol 1999;104:208-19.
32. Gross SJ, Filston HC, Anderson JC. Controlled study of treatment for disseminated intravascular coagulation in the neonate. J Pediatr 1982;100:445-8.
33. Hardy JF, de Moerloose de P, Samama CM. The coagulopathy of massive transfusion. Vox Sang 2005;89:123-7.
34. Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007;62:112-9.
35. Johansson PI, Stensballe J, Rosenberg I, et al. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: Evaluating a change in transfusion practice. Transfusion 2007;47:593-8.
36. Foster PF, Moore LR, Sankary HN, et al. Central venous catheterization in patients with coagulopathy. Arch Surg 1992;127:273-5.
37. DeLoughery TG, Liebler JM, Simonds V, Goodnight SH. Invasive line placement in critically ill patients: Do hemostatic defects matter? Transfusion 1996;36:827-31.
38. Fisher NC, Mutimer DJ. Central venous cannulation in patients with liver disease and coagulopathy-a prospective audit. Intensive Care Med 1999;25:481-5.
39. Doerfler ME, Kaufman B, Goldenberg AS. Central venous catheter placement in patients with disorders of hemostasis. Chest 1996;110:185-8.
40. Dara SI, Rana R, Afessa B, et al. Fresh frozen plasma transfusion in critically ill medical patients with coagulaopathy. Crit Care Med 2005;33:2667-71.
41. Gajic O, Dzik WH, Toy P. Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: Benefit or harm? Crit Care Med 2006;34:S170-S173.
42. Gazzard B G , Henderson J M, Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 1975;16:617-20.
43. Youssef WI, Salazar F, Dasarathy S, et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: A dual phase study. Am J Gastroenterol 2003;98:1391-4.
44. McVay PA, Toy PTCY. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990;94:747-53.
45. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005;41:553-8.
46. Peterson GA. Does systematic anticoagulation increase the risk of internal jugular vein cannulation? (letter) Anesthesiology 1991;75:1124.
47. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: An evidence-based review. Transfusion 2005;45:1413-25.
48. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007;21:37-48.
49. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulapoathy. Thromb Haemost 1997;77:477-80.
50. Shehata N, Kouroukis C, Kelton JG. A review of randomized controlled trials using therapeutic apheresis. Transfus Med Rev 2002;16:200-29.
51. Rock GA, Shumak KH, Buskard NA for the Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of TTP. N Engl J Med 1991;325:393-7.
52. Fontana S, Kremer Hovinga JA, Lammle B, Taleghani BM. Treatment of thrombotic thrombocytopenic purpura. Vox Sang 2006;90:245-54.
53. Chirnside A, Urbaniak SJ, Prowse CV, Keller AJ. Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol 1981;48:627-34.
54. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion. Am J Clin Pathol 2006;126:133-9.
55. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006;46:1279-85.
56. Chowdhury P, Saayman AG, Paulus U, et al. Efficacy of standard dose and 30 mL/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004;125:69-73.
57. Holland L, Sarode R. Should plasma be transfused prophylactically before invasive procedures? Curr Opin Haematol 2006;13:447-51.
58. Williamson LM, Llewelyn CA, Fisher NF, et al. A randomised trial of solvent/detergent and standard fresh frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999;39:1227-34.
59. Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep 2004;3:324-30.
60. Keeling D. International normalised ratio in patients not on vitamin K antagonists. J Thromb Haemost 2007;5:188-9.
61. Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet 2002;359:47-8.
62. Pamphilon DH. Viral inactivation of FFP. Br J Haematol 2000;109:680-93.
63. Pelletier JPR, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006;19:205-42.
64. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006;107:3753-60.
65. Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003;121:778-85.
66. Atance R, Pereira A, Ramirez B. Transfusing methylene blue- photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001;41:1548-52.
67. Raife TJ, Friedman KD, Dwyre DM. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: Reconsideration of treatment with cryo-poor plasma. Transfusion 2006;46:74-9.
68. Luk C, Eckert KM, Barr RM, Chin-Yee IH. Prospective audit of the use of fresh-frozen plasma, based on Canadian Medical Association transfusion guidelines. Can Med Assoc J 2002;166:1539-40.
69. Schofield WN, Rubin GL, Dean MG. Appropriateness of platelet, fresh frozen plasma and cryoprecipitate transfusion in New South Wales public hospitals. Med J Aust 2003;178:117-21.
70. Jones HP, Jones J, Napier JA, al-Ismail S. Clinical use of FFP: Results of a retrospective process and outcome audit. Transfus Med 1998;8:37-41.
71. Cheng G, Wong HF, Chan A, Chui CH. The effects of a self- educating blood component request form and enforcements of transfusion guidelines on FFP and platelet usage. Queen Mary Hospital, Hong Kong. British Committee for Standards in Hematology (BCSH). Clin Lab Haematol 1996;18:83-7.
72. Brien WF, Butler RJ, Inwood MJ. An audit of blood component therapy in a Canadian general teaching hospital. Can Med Assoc J 1989;140:812-5.
73. Blumberg N, Laczin J, McMican A, et al. A critical survey of fresh- frozen plasma use. Transfusion 1986;26:511-3.
74. Silbert JA, Bove JR, Dubin S, Bush WS. Patterns of frozen plasma use. Conn Med 1981;45:507-11.
75. Eccles M, Grimshaw J, Walker A, et al. Changing the behaviour of healthcare professionals: The use of theory in promoting the uptake of research findings. J Clin Epidemiol 2005;58:107-12.
76. Doust J, Del Mar C. Why do doctors use treatments that do not work? Br Med J 2004;328:474-5.
77. Wilson K, MacDougall L, Fergusson D, et al. The effectiveness of interventions to reduce physicians' levels of inappropriate transfusion: What can be learned from a systematic review of the literature. Transfusion 2002;42:1224-9.
78. Tinmouth A, MacDougall L, Fergusson D, et al. Reducing the amount of blood transfused: A systematic review of behavioral interventions to change physicians' transfusion practices. Arch Intern Med 2005;165:845-52.
79. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: A systematic review of randomised trials. Br Med J 1998;316:961-4.
80. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. Meta-analysis of randomized controlled trials. Ann Intern Med 2001;135:149-64.
81. The SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-56.